Mona Magdy
mona.magdy@ejust.edu.eg
Personal Info
01004561141
Clinical Pharmacy Department
Dr. Mona M. Saber, Ph.D.
Associate Professor of Pharmacology and Toxicology
Faculty of Pharmacy, Cairo University, Egypt
Dr. Mona M. Saber is an accomplished biomedical research scientist and academic with extensive experience in pharmacology, toxicology, and molecular medicine. She earned her Ph.D. in Pharmaceutical Sciences from Cairo University in collaboration with Heinrich Heine University, Düsseldorf, Germany, through a prestigious DAAD German Egyptian Research Scholarship (GERSS).
Her postdoctoral and academic work has centered on understanding the molecular basis of cancer and inflammation, with a special emphasis on drug repurposing, nanomedicine, and signaling crosstalk in cancer therapy. Dr. Saber has made significant contributions to the study of metformin, cisplatin, and 5-aminosalicylic acid combinations, as well as to the development of nanoformulations for targeted drug delivery.
In addition to her laboratory research, Dr. Saber plays an active role in mentoring postgraduate students and fostering collaborations across disciplines and institutions. She has supervised numerous M.Sc. and Ph.D. candidates and participated in internationally funded research projects, including collaborations with the Institute of Molecular Medicine in Germany and the Academy of Scientific Research and Technology (ASRT) in Egypt.
Her research has been published in leading international journals such as BMC Cancer, Life Sciences, Journal of Ethnopharmacology, and European Journal of Pharmaceutics and Biopharmaceutics. Dr. Saber has also presented her findings at global conferences in Europe and the Middle East and has received multiple awards for international scientific publication and research excellence.
Beyond research, Dr. Saber is committed to academic leadership and community service. She currently serves as Head of the Clinical Pharmacy Department at the Modern University for Technology and Information, and has taught at several universities including New Giza University, Galala University, and the British University in Egypt. She is also actively involved in health awareness initiatives and faculty quality assurance committees.
My research focuses on exploring the pharmacological and molecular mechanisms underlying cancer progression, inflammation, and metabolic disorders. My work integrates cellular signaling, molecular pharmacology, and nanotechnology-based drug delivery to design innovative therapeutic strategies that enhance drug efficacy and reduce toxicity.
My research specifically targets signaling pathways regulating apoptosis, necroptosis, autophagy, and mitochondrial dynamics within the tumor microenvironment, emphasizing how inflammation and metabolic alterations fuel cancer growth. I am also interested in cardio-oncology, particularly in elucidating the mechanisms of chemotherapy-induced cardiotoxicity and investigating protective interventions using GLP-1 analogs, statins, and natural products.
In addition, I have a growing research interest in nanomedicine, where I design and characterize nanoformulations such as cubosomes, spanlastics, and polymeric nanoparticles to improve targeted delivery in cancer, inflammatory bowel disease, and skin disorders. My interdisciplinary approach bridges pharmacology, toxicology, and molecular biology to address current challenges in translational and precision medicine.
Key areas of focus:
-
Cancer pharmacology and tumor microenvironment
-
Apoptosis, necroptosis, and autophagy signaling pathways
-
Metabolic and inflammatory signaling in disease progression
-
Chemotherapy-induced cardiotoxicity and cardioprotection
-
Nanoparticle formulation and targeted drug delivery
-
Translational pharmacology and personalized therapeutics
